Image courtesy of Stryker.

Register to receive a free U.S. Market Report Suite for Neurological  Devices report synopsis and brochure

Stryker recently launched the Surpass Evolve Flow Diverter following approval in March. Surpass Evolve is Stryker’s newest product release into the flow diversion space for the treatment of brain aneurysms. Improving on the already successful existing Surpass platform, this new device has been designed to maximize overall usage and allow physicians advanced control through  procedures.

“The Surpass Evolve Flow Diverter is the culmination of many years of flow diversion research, extensive physician feedback from around the world and Stryker engineering prowess. This high performing device will be a great addition to our hemorrhagic portfolio to help physicians in the treatment of brain aneurysms” said Mark Paul, President, Stryker’s Neurovascular division.

In recent years, the usage of flow diversion technology for the treatment of brain aneurysms has grown in usage and acceptance. Flow diverters allow physicians to successfully treat their patients suffering from brain aneurysms without needing to enter the sac of the aneurysm itself.

Once the first medical procedures were conducted, Dr. Vitor Mendes Pereira, Neuroradiologist at Toronto Western Hospital’s Joint Department of Medical Imaging stated, “Surpass Evolve represents an exciting advancement in the treatment of complex brain aneurysms. The device is easy to use, highly responsive and demonstrates a strong flow diversion for aneurysm healing.”

An aneurysm occurs when part of a blood vessel becomes weak, causing the vessel to balloon or bulge and fill with blood. Aneurysms can occur in any blood vessel in the body. However, brain aneurysms are the most life-threatening. If left untreated, the aneurysm may continue to weaken until it bursts and bleeds into the brain. Almost 500,000 deaths occur each year as a result of a brain aneurysm.

According to iData Research, one of the major market drivers for neurological devices is the patient and physicians demand for minimally invasive procedures. This has been driving the growth in interventional neuroradiology and neuroendoscopy. This has led to procedural growth in endovascular embolization treatments and a decline in aneurysm clipping procedures treatments. Access devices are becoming increasingly technologically advanced and various embolization devices have been released in recent years. Following the demand for minimally invasive procedures, Stryker’s Surpass Evolve Flow Diverter couldn’t have been given approval at a better time, as it avoids entering the aneurysm sac in brain aneurysm treatment.

Source

For Further Information

More on the neurological device market can be found in a series of reports published by iData entitled the U.S. Market Report Suite for Neurological  Devices